Clinical Research Directory

Clinically suspected complicated CL patients visiting the study site meeting the following inclusion criteria and none of the exclusion criteria: Inclusion: * Clinical diagnosis of CL * Need for systemic treatment (1 or more of these criteria) * Mucosal involvement of lesion or at risk for mucosal involvement (\< 1 cm from the nose, eyes and vermillion border of the lips) * Lesion size \>4 cm * \>4 lesions * Lesions on joints or fingers * Lesions previously not responding to local treatment * Lesions unsuitable for local treatment (e.g., eyelids) * Lesions with signs of dissemination (satellite lesions, nodular lymphangitis, sporotrichoid pattern) * Age \> 4 (minimum age to receive systemic treatment with SSG) * At least one lesion eligible for treatment\* (meeting all criteria below) * lesion with surface change, including ulcerated, crusted and scaly lesions * distinguishable from other lesions (minimum 0.5 cm apart) * no mucosal involvement against which a topical agent would likely not be effective (e.g., lesions that are located too deep within the nasal passages or on the inner lip, where proper application is challenging and the ointment may be easily removed or not adequately absorbed) * Willing and able to provide informed consent. For participants under the age of 18, parental or caregiver consent is required. Additionally, assent must be obtained from adolescents aged 12 to 17 * Willing to be hospitalized for 4 weeks Exclusion: * DCL patients * Only lesions not eligible for treatment\* * Currently on treatment or having received non-traditional antileishmanial treatment (cryotherapy, thermotherapy, sodium stibogluconate, meglumine antimoniate, paromomycin, pentamidine, AmBisome, miltefosine, non-liposomal amphotericin B) in the past 1 month * Currently on or having received topical antibiotic treatment for CL lesion(s) in the past 1 month * Currently on or having received systemic antibiotic treatment in general in the past 1 month * Currently in need for systemic antibiotics * Pregnant (positive pregnancy test at D0) or breastfeeding * Abnormal lab values * Hemoglobin \< 5.0g/100mL * Platelets \< 50 x 10\^9/L * White blood count \< 1 x 10\^9/L * ASAT/ALAT \> 3x upper normal range * Creatinine above the normal limit * Prolonged QTc interval or arrythmia on ECG or history of arrythmias * Known serious kidney or liver disease * Known allergies to one of the study components/medications * Serious adverse reaction to a previous SSG dose \*If a patient has multiple lesions, of which some are eligible for treatment and others are not, the patient can still be involved in the study. Only the eligible lesions will be subjected to treatment and outcome assessment.